| abstract |
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycinnis provided, which is useful in the treatment and prevention ofntransplant rejection and also certain autoimmune and inflammatory diseases, together with novelnpharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with anrapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin. |